Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (NCT03256045), a na phase 2 study. The primary outcome is Best Overall Response, by Subject.

2. Clinical Question

3. Trial Design

This was a phase II, single-group study registered as NCT03256045. The registry lists an enrollment of 9 and a status of terminated. The recorded start date is 2018-02-08, and the primary completion date is 2021-02-05. The reason for termination is not reported in the registry record.

All participants were assigned to the treatment group described in the registry: panobinostat, carfilzomib, and dexamethasone, with chemosensitivity testing and laboratory biomarker analysis. The treatment schedule specified panobinostat by mouth on days 1, 3, 5, 15, 17, and 19, and carfilzomib intravenously plus dexamethasone by mouth on days 1, 2, 8, 9, 15, and 16. The planned cycle length was 28 days, with treatment for up to 12 cycles unless disease progression or unacceptable toxicity occurred.

Allocation is listed as not applicable, masking as none, and the study model as single group. These features mean the results cannot be interpreted as a randomized treatment contrast. Without a concurrent comparator, changes in disease status cannot be separated from other possible influences using a between-group comparison. This is a general limitation of single-group designs, not a finding about what caused any individual outcome.

The registry describes both clinical response assessment and laboratory work using myeloma cells from blood samples. Its brief description says laboratory tests were intended to examine the effects of individual drugs and combinations on those cells, with a possible future role in treatment planning. However, laboratory results, their relationship to clinical outcomes, and further protocol details are not reported in the registry record. The registry record also does not report the reason the study was terminated or whether all planned participants completed treatment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Best Overall Response, by Subject, measured over 14 months.

The primary outcome is titled best overall response, by subject, and is measured using International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. The stated timeframe is 14 months. The registry codes the response categories as follows: 1 is very good partial response (VGPR), 2 is partial response (PR), 3 is minimal response (MR), 4 is stable disease (SD), and 5 is progressive disease (PD).

In general, a best overall response endpoint classifies the best response recorded for each participant during a defined assessment period. It can describe the range of clinical response categories observed in a study. The ordered categories carry different clinical meanings, but their numeric codes are labels; the distance between one code and the next should not be treated as a measured quantity. This is a general point about category coding.

The registry record identifies the endpoint and its criteria but does not report the number of participants in each response category, an overall response estimate, or uncertainty around any estimate. It also does not report how response assessments were collected or how participants without an evaluable assessment were handled. Thus, the endpoint definition is available, but the posted record does not permit an assessment of the response distribution or its precision.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record identifies a single-group phase II study and a categorical primary outcome, but does not report the statistical analysis methods used for the clinical endpoint. The explanations below describe general statistical concepts relevant to reading such a design; they are not claims about analyses conducted in this study.

What does a single-group design estimate?

In general, a single-group study can describe outcomes among the participants who received the study treatment. It does not, by itself, estimate what would have happened to comparable participants under a different treatment or without the study treatment. A randomized comparator can help distinguish a treatment contrast from differences in participant characteristics, changes over time, or other influences. This study has no separate comparator group, so a treatment-versus-control contrast is not part of the reported design.

The distinction is important when interpreting a clinical response. A response category can be observed and described, but an outcome occurring after treatment does not alone show that treatment caused it. In a single-group design, the observed response distribution is descriptive unless supported by a suitable comparison or other clearly specified causal analysis. No such comparative analysis is reported in the registry record.

How should the response categories be read?

In general, a categorical endpoint assigns each participant to a defined response class. Here, the recorded classes range from very good partial response through partial response, minimal response, stable disease, and progressive disease, with numerical codes 1 through 5. These codes identify categories rather than quantities. Treating the difference between two adjacent codes as numerically equal to the difference between another pair would impose a scale interpretation that the category labels do not establish.

A category distribution is often more informative than a single average code because it preserves the meaning of each response class. To understand an observed distribution, readers would need the count in each category and the number of participants assessed. The registry record does not report those counts. It also does not report a rule for handling multiple assessments when selecting a participant’s best response, beyond naming the outcome as best overall response.

What does statistical uncertainty mean?

In general, a confidence interval describes a range of values compatible with the observed data under a stated statistical model and sampling assumptions. It helps convey precision, rather than determining whether a result is clinically important. A small study group commonly yields less precise estimates than a larger group, although the actual precision depends on the outcome and analysis. No confidence interval for the primary outcome is reported in the registry record, so its precision cannot be quantified from the posted results.

A p-value, when used, summarizes how unusual the data would be under a specified null hypothesis and statistical model. It is not a measure of the size or importance of an effect. The registry record does not report a p-value or a primary-outcome analysis. No significance claim can therefore be evaluated from the posted record.

How does the laboratory objective differ from the clinical endpoint?

The clinical endpoint classifies participant response. The laboratory objective, as described in the registry, concerns tests on myeloma cells from blood samples and their response to drugs alone or in combinations. These are related research questions but distinct measurements. In general, a laboratory assay can be compared with clinical outcomes to examine whether assay results track with response; such an analysis requires assay measurements, clinical outcome data, and a specified statistical approach. The registry record does not report assay results, a correlation estimate, or the method used to assess any association.

Even when two measurements are associated, association alone does not show that one causes the other or that a test can guide decisions accurately. General evaluation of a proposed assay may consider reproducibility, the strength and uncertainty of the association, and performance in an appropriate population. The registry record does not report those evaluations, so the stated possibility of future treatment planning should not be read as evidence that the assay has been validated for that purpose.

What do the planning assumptions mean?

In general, a sample-size illustration uses assumptions about a target effect, a significance level, allocation, and a statistical model to describe the size of a hypothetical study. The record’s stated illustration uses a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the target effect described as a fraction of the observed effect. It distinguishes participants per arm for non-time-to-event outcomes from total events for time-to-event outcomes.

Those assumptions are planning illustrations, not the original design justification for this study and not observed power. The two-arm equal-allocation assumption does not describe this single-group design. The registry record does not report the original sample-size justification or the numerical planning estimates in the registry record for this analysis. In general, a planning calculation based on an observed effect is sensitive to that effect estimate, particularly when the estimate comes from a small study. It should not be interpreted as a guarantee that a later study would achieve a particular result.

Overall, statistical interpretation requires separating what is defined from what is observed, and separating descriptive results from comparative inference. The endpoint definition and design are recorded, but the primary response values and analysis methods are not. General concepts can clarify what those missing elements would contribute, but cannot substitute for them.

10. Multiplicity, Missing Data and Analysis Populations

The registry record identifies one primary outcome and lists 6 outcome measures in total. It does not report a statistical plan explaining how the primary outcome and other outcomes were prioritized or analyzed. Multiplicity methods, such as an adjustment for testing several hypotheses, are not reported in the registry record. This does not establish that no such methods were used; it means the record does not describe them.

In general, conducting multiple statistical tests can increase the chance of finding at least one apparently unusual result by chance. A prespecified analysis plan can clarify which outcomes and comparisons are confirmatory and how multiple testing is addressed. The registry record does not report such a plan, and it does not report analyses for the primary outcome.

Missing-data handling and analysis populations are also not reported in the registry record. It is not stated how participants who stopped treatment, lacked a response assessment, or had incomplete laboratory measurements were handled. The record does not specify whether analyses used all enrolled participants, only participants with an evaluable outcome, or another defined population. These details matter in general because different inclusion and missing-data rules can change the denominator and interpretation of an estimate.

Interim analyses and any stopping rules are not reported in the registry record. The study status is terminated, but the reason for termination and its relationship, if any, to planned analyses are not reported. No conclusion about an interim review or the reason for termination can be drawn from status alone.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: non-st segment elevation myocardial infarction (11.1%), fracture, pathologic (11.1%), fracture, non-pathologic (11.1%), fall (11.1%).

The registry record lists 9 participants at risk for both serious and other adverse events. Serious adverse events affected 3 participants, and other adverse events affected 4 participants. The record lists 0 deaths. These are counts for the study group; no concurrent comparator is available for a relative safety comparison.

The listed serious-event terms are non-ST segment elevation myocardial infarction, pathologic fracture, non-pathologic fracture, and fall. Each is reported with an incidence of 11.1%. The record does not state whether participants could contribute more than one term, so the terms should not be added to infer a total number of affected participants. Nor does the listing establish that each term occurred in a different person.

In general, adverse-event summaries depend on the definitions used, the period of observation, and how events are grouped and attributed. The registry record does not report event timing, duration, severity grades, or an assessment of relationship to treatment for these terms. The counts describe what is posted; they do not establish that treatment caused an event or permit comparison with another regimen. Zero deaths in the recorded group is a reported count, not evidence about risks outside this study.

12. What the Result Does, and Does Not, Mean

The record documents a phase II study of panobinostat, carfilzomib, and dexamethasone in relapsed or refractory multiple myeloma. It lists 9 enrolled participants, a single treatment group, and a best overall response endpoint assessed using International Myeloma Working Group criteria. It also describes laboratory chemosensitivity testing and biomarker analysis. These registry entries explain the study’s focus, but they do not supply the clinical or laboratory results needed to judge the observed response pattern.

The posted safety information records serious and other adverse events and reports 0 deaths. Those counts can describe events among the enrolled group, but cannot establish comparative safety without a control group. The record also does not provide event timing, severity grading, or attribution to treatment. They should therefore be read as registry counts rather than as a complete account of risk.

The absence of posted response and assay findings does not mean that no response or laboratory findings occurred. It means those results are not reported in the registry record. Likewise, the lack of a comparator means the record does not estimate a treatment contrast; it does not establish that the regimen had no effect. No conclusion about benefit, lack of benefit, or a validated assay-guided approach follows from the information recorded.

In general, evaluating a treatment requires considering the outcome definition, observed results, uncertainty, study design, and completeness of reporting together. For this study, the design and outcome definition are described, but the primary response distribution, analysis methods, and assay results are not. The appropriate interpretation is therefore limited: the registry identifies the research question and records selected safety counts, while leaving the primary clinical and laboratory findings unavailable for statistical assessment.

13. Why This Trial Matters Statistically

This study is statistically notable for bringing a clinical response question and a laboratory chemosensitivity question into the same research program. The registry describes testing myeloma cells from blood samples against drugs alone and in combinations, alongside treatment with panobinostat, carfilzomib, and dexamethasone. In general, linking a laboratory measure to a clinical outcome raises questions about whether the assay is associated with response and whether that relationship is sufficiently reproducible and precise to be useful. The registry record does not report the results needed to answer those questions.

The single-group design also makes the distinction between describing outcomes and estimating treatment effects especially important. A response distribution could describe what happened among participants, but a comparator would be needed for a direct concurrent treatment contrast. The registry lists an enrollment of 9, making transparent reporting of denominators and uncertainty particularly relevant as a general statistical concern.

The endpoint is categorical, with response classes defined by the International Myeloma Working Group criteria. Such endpoints should be interpreted through their category meanings rather than by treating the numeric labels as a continuous scale. Without the category counts, however, readers cannot assess the distribution itself.

Finally, the record shows how much interpretation depends on complete reporting. The study status is terminated, yet the reason is not reported; the primary outcome is defined, yet its values and analyses are not reported. These gaps prevent a full statistical account of the clinical and laboratory questions. The study remains a useful example of why design, outcome definitions, analysis plans, and results need to be read together, without treating a research aim as a demonstrated finding.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this study constrain interpretation. It was a single-group study with allocation listed as not applicable and masking as none. There was no like-for-like control comparison, so the registry record cannot support a direct treatment-versus-control estimate. This design also leaves clinical response descriptions vulnerable to influences that a concurrent comparison might help assess.

The registry lists an enrollment of 9, but does not report the number of participants with an evaluable primary outcome or the response category counts. It is therefore not possible to assess the response distribution, denominators for that endpoint, or precision from the posted record. The primary endpoint is defined for a 14 months timeframe, but the outcome values are not reported.

The laboratory component is described as testing blood-sample myeloma cells for sensitivity to drugs alone and in combinations. However, assay measurements, clinical-assay associations, and methods for assessing those associations are not reported in the registry record. The record therefore does not establish whether the laboratory objective was achieved or whether the assay findings were informative about clinical response.

The study is marked terminated, but the reason for termination is not reported. The registry record also does not report the statistical analysis plan, interim analyses, missing-data approach, or analysis populations. For safety, it gives selected counts and event terms but does not report event timing, severity grades, or treatment attribution. These limitations do not determine what the unreported results would show; they define what can be concluded from the record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma — NCT03256045.
• Registry record last updated 2022-05-09; status last verified 2022-05.
• Results first posted 2022-05-09.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT03256045 is a phase II, single-group study of panobinostat, carfilzomib, and dexamethasone in relapsed or refractory multiple myeloma. The registry lists 9 enrolled participants, no masking, and a terminated status. The recorded start date is 2018-02-08, and the primary completion date is 2021-02-05.

The primary outcome is best overall response by International Myeloma Working Group criteria, with a 14 months timeframe. The record also describes chemosensitivity testing and laboratory biomarker analysis. It does not report primary response values, assay findings, or analyses. Safety counts include 3 participants with serious adverse events, 4 with other adverse events, and 0 deaths; four serious-event terms are listed at 11.1% each. The reason for termination and key analysis details are not reported in the registry record.